Liver fibrosis improvement assessed by magnetic resonance elastography and Mac-2-binding protein glycosylation isomer in patients with hepatitis C virus infection receiving direct-acting antivirals

Natthaya Chuaypen¹ | Salyavit Chittmittrapap¹ | Anchalee Avihingsanon² | Surachate Siripongsakun³ | Jongkonnee Wongpiyabovorn⁴ | Natthaporn Tanpowpong⁵ | Yasuhito Tanaka⁶ | Pisit Tangkijvanich¹

¹Center of Excellence in Hepatitis and Liver Cancer, Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
²The HIV Netherlands Australia Thailand Research Collaboration (HIV NAT), Department of Medicine, Bangkok, Thailand
³Sonographer School, Department of Medical Imaging, Faculty of Health Science Technology, Chulabhorn Royal Academy, Bangkok, Thailand
⁴Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
⁵Department of Radiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
⁶Department of Virology and Liver Unit, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

Abstract

Aim: Fibrosis regression has been observed in patients with chronic hepatitis C virus (HCV) infection treated with direct-acting antivirals. This study was aimed at evaluating dynamic changes of serum Mac-2-binding protein glycosylation isomer (M2BPGi) in patients with HCV genotype 1 receiving elbasvir/grazoprevir.

Methods: M2BPGi were serially measured at baseline, during and after therapy. Its diagnostic performance at baseline and sustained virological response at 24 weeks after treatment (SVR24) were compared with transient elastography (TE) and the aspartate aminotransferase/platelet ratio index (APRI) using magnetic resonance elastography (MRE) as a reference.

Results: Overall, 60 HCV mono-infected and 36 HCV/HIV co-infected patients were included with SVR24 rates of 93.3% and 97.2%, respectively. At baseline, TE, M2BPGi and APRI were correlated with MRE (r = 0.788, r = 0.703 and r = 0.564, respectively, p < 0.001). The area under the receiver operator characteristics curves for TE, M2BPGi and APRI in differentiating significant fibrosis were 0.88 (95% confidence interval; 0.81–0.95, p < 0.001), 0.86 (0.79–0.94, p < 0.001) and 0.74 (0.64–0.83, p < 0.001), respectively. The corresponding figures for cirrhosis were 0.95 (0.90–1.00, p < 0.001), 0.96 (0.92–1.00, p < 0.001) and 0.88 (0.79–0.97, p < 0.001), respectively. Compared with baseline, all fibrosis markers significantly declined after achieving SVR24. The correlations of TE, M2BPGi and APRI with MRE at time of SVR24 were r = 0.587 (p < 0.001), r = 0.457 (p < 0.001) and r = 0.293 (p = 0.004), respectively. In multivariate analysis, high baseline alanine aminotransferase level, HCV mono-infection and advanced fibrosis were factors associated with M2BPGi reduction.

Abbreviations: ALT, alanine aminotransferase; APRI, AST/platelet ratio index; AST, aspartate aminotransferase; AUROCs, area under the ROC curves; CI, confidence interval; COI, cutoff index; DAAs, direct-acting antivirals; EBR/GZR, elbasvir/grazoprevir; EOT, end of treatment; GT1, HCV genotype 1; HCC, hepatocellular carcinoma; HCV, hepatitis C virus infection; HIV, human immunodeficiency virus; MRE, magnetic resonance elastography; M2BPGi, Mac-2 binding protein glycosylation isomer; PEG-IFN, pegylated interferon; RBV, ribavirin; ROC, receiver operator characteristics; SVR, sustained virological response; SVR24, sustained virological response at 24 weeks after treatment; TE, transient elastography.
INTRODUCTION

Hepatitis C virus (HCV) infection is a worldwide public health concern, with an estimated 180 million people chronically infected with the virus. Currently, the prevalence of chronic HCV infection in Thailand is approximately 2%. Based on the natural history of chronic HCV infection, it is estimated that 10%–20% of patients will develop cirrhosis and these cirrhotic patients will develop hepatocellular carcinoma (HCC) at an annual rate of 2%–7%. The risk of cirrhosis is increased in individuals with older age at infection, heavy alcohol intake, concomitant obesity and co-infection with human immunodeficiency virus (HIV). HCV/HIV co-infected patients are at three-fold greater risk for progression to cirrhosis or liver decompensation and at 10-fold greater risk for liver-related mortality compared with HCV mono-infected patients. Our recent cross-sectional data showed that advanced liver fibrosis was more commonly found in HCV/HIV co-infected individuals than in the mono-infected group (41% vs. 25%). Previously, a standard of care for chronic HCV infection was the combination of pegylated interferon (PEG-IFN) and ribavirin (RBV). However, the response rate of this regimen was poor, particularly among HCV/HIV co-infected patients with genotype 1 (GT1) and advanced fibrosis. With the introduction of direct-acting antivirals (DAAs), HCV treatment has been revolutionized, as HCV mono- and HCV/HIV co-infected individuals could achieve sustained virological response (SVR) rates >90%. It has been shown that SVR is associated with a very low risk of HCV reactivation and a reduced risk of the progression of cirrhosis and HCC development.

An accurate assessment of liver fibrosis stages is necessary for the management of patients with chronic HCV infection. Although liver biopsy has been considered a gold standard in assessing liver histopathology, this procedure has some limitations because of its potential of life-threatening complications and sampling errors. In addition, the longitudinal evaluation of liver fibrosis is restricted due to the invasiveness of the procedure. An alternative non-invasive tool to measure the severity of liver fibrosis is transient elastography (TE), which has been validated in both HCV mono-infected and HIV/HCV co-infected patients. Besides ultrasound-based techniques, magnetic resonance elastography (MRE) has been shown to be a highly accurate, non-invasive technique for the diagnosis and staging of liver fibrosis, regardless of inflammation and etiology of liver diseases. Compared with TE, MRE provides a better diagnostic performance in the identification of liver fibrosis and cirrhosis in patients with chronic viral hepatitis or non-alcoholic fatty liver disease. In addition, patients with chronic HCV infection who achieved SVR after DAAs therapy showed subsequent improvement of liver stiffness based on MRE. With the advantages of its accuracy and reproducibility, MRE is now considered as the most reliable non-invasive technique for the assessment of liver fibrosis.

Besides imaging-based techniques, several serum fibrosis markers have been applied to evaluate the extent of liver fibrosis. Recently, the serum Mac-2-binding protein glycosylation isomer (M2BPGi) has emerged as a novel non-invasive marker for liver fibrosis, particularly in patients with chronic HCV infection. In addition, M2BPGi can also be used to predict HCV treatment outcome, including regimens with PEG-IFN- or DAAs-based therapies. Despite these data, there are limited studies that directly examine the usefulness of serial M2BPGi in monitoring fibrosis regression following DAAs treatment. Therefore, this study was aimed at investigating the clinical utility of serum M2BPGi kinetics during elbasvir/grazoprevir (EBR/GZR) therapy in HCV mono-infected and HIV/HCV co-infected patients. Moreover, the diagnostic performance of serum M2BPGi at baseline and after therapy was compared with TE and aspartate aminotransferase/platelet ratio index (APRI) score by using MRE as a reference.

MATERIALS AND METHODS

Patients

Patients treated with EBR/GZR and recruited via clinicaltrials.gov (NCT03037151) at the King Chulalongkorn Memorial Hospital, Bangkok, Thailand between August 2018 and June 2019, were enrolled in this study. Inclusion criteria for EBR/GZR therapy were patients with anti-HCV positive levels for at least 6 months, detectable HCV RNA levels >10 000 IU/ml and infected with HCV GT1, irrespective of liver fibrosis. For patients with HCV/HIV co-infection, each individual received antiretroviral therapy with undetectable plasma HIV-RNA levels. Exclusion criteria were hepatitis B virus co-infection, previous treatment with DAAs, clinical evidence suggestive of decompensated cirrhosis or HCC by imaging studies. Treatment-naive patients assigned to treatment with EBR/GZR for 12 weeks, while treatment-experienced patients, including...
null responders, partial responders or post-treatment relapers following PEG-IFN/RBV, were treated with EBR/GZR plus weight-based RBV for 16 weeks. Patients were followed up to assess SVR (defined by HCV RNA level <12 IU/ml) at weeks 12 and 24 after therapy cessation (SVR12 and SVR24, respectively).

The study protocol, conducted in compliance with the Helsinki Declaration and Good Clinical Practice guidelines, was approved by the Institutional Review Board of the Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. Written informed consent was obtained from all patients for the use of their clinical data and sample specimens.

**Laboratory assays**

Routine laboratory tests such as complete blood count (CBC) and biochemical tests (e.g., aspartate aminotransferase [AST] and alanine aminotransferase [ALT]) were determined at the central laboratory of the King Chulalongkorn Memorial Hospital. APRI score was calculated by the formula (AST/upper limit of normal considered as 40 IU/L)/platelet count (10⁵/L) × 100.²²

HCV RNA quantification was performed using real-time quantitative reverse–transcription polymerase chain reaction (Abbott Molecular Inc.) in accordance with the manufacturer’s instructions. The lower detection limit of the assay was <12 IU/ml. HCV genotypes were determined by nucleotide sequencing of the core and NS5B regions as described previously.³ Plasma HIV RNA level is assessed using the Abbott RealTime HIV-1 Assay (Abbott Molecular Inc.).

Serum samples for M2BPGi testing were collected from the participants and stored at −70°C until analysis. Serial serum M2BPGi measurements at baseline, week 4 of treatment, end of treatment (EOT), 12 weeks after EOT (SVR12) and 24 weeks after EOT (SVR24) were assessed by lectin-antibody sandwich immunoassay using a fully automatic immune-analyzer HISCL-2000i (Sysmex). The measured values of M2BPGi were calculated by the following equation: cutoff index (COI) = ([M2BPGi]sample − [M2BPGi]negative controls)/([M2BPGi]positive controls − [M2BPGi]negative controls).²³

**Transient elastography**

Liver stiffness was measured at baseline and SVR24 using TE (Echosens) with M-probe and XL-probe as appropriate. The procedure was based on at least 10 validated measurements with a success rate >60% and interquartile range <30%. Results were recorded in kilopascals (kPa) as the median value of all measurements.²⁴

**Magnetic resonance elastography**

MRE was performed within 2 weeks before starting DAAs and within 2 weeks of SVR24, using the MR imaging system Philips Ingenia at 3.0T (Philips Healthcare) according to the method described previously²⁵ and the examinations were performed by the hardware and software leased from Resoundant. Briefly, at the beginning of each examination, a passive driver was placed on the patient’s right upper abdomen to transmit low-amplitude 60-Hz vibrations to the liver for the generation of shear waves using a 2D GRE MRE pulse sequence. Liver stiffness was measured in three slices, and an average value expressed in kPa was obtained. Based on a previous study in patients with chronic HCV infection, liver stiffness cutoff values for significant fibrosis (≥F2), advanced fibrosis (≥F3) and cirrhosis (F4) were 3.2, 4.0 and 4.6 kPa, respectively.²⁶

**Statistical analyses**

Data were expressed as percentages or mean ± standard deviation. Comparisons between groups were analyzed by the χ² or Fisher’s exact test for categorical variables and by two-sample t-tests for continuous variables as appropriate. Changes in liver stiffness and serum fibrosis markers post-treatment were compared with pretreatment levels by paired t-tests. The diagnostic performances of TE, M2BPGi and APRI were evaluated by calculation of the receiver operator characteristics (ROC) curves using MRE as the reference. Correlations between each parameter were tested by the Spearman’s rank test. The logistic regression analysis was performed to evaluate parameters associated with serum M2BPGi reduction. For regression analysis, the median value of each continuous variable was used as the cutoff point. p < 0.05 was designated as a statistical significance. Statistical analyses were performed by the IBM SPSS software version 23.0 (IBM Corp., Armonk, NY, USA).

**RESULTS**

**Baseline clinical characteristics and treatment outcome**

Initially, 101 patients with HCV GT1, who treated with EBR/GZR were recruited from clinical trial (NCT03037151). However, three patients did not perform MRE at baseline and post-treatment due to claustrophobia and another two patients did not perform MRE after completing the therapy. Apart from these five patients, 96 patients with complete clinical data and liver stiffness measurement were included in this study. Baseline clinical characteristics regarding HIV status are summarized in Table 1. The patients consisted of 74 (77.1%) men and 22 (22.9%) women with a mean age of 47.0 ± 10.8 years. Among these patients, there were 60 (62.5%) individuals with HCV mono-infection and 36 (37.5%) with HCV/HIV co-infection. Compared with the co-infected group, patients with HCV mono-infection had significantly higher average age, body mass index (BMI), APRI score and the distribution of HCV GT1b. There was no significant difference between the two groups in terms of biochemical parameters, previous PEG-IFN/RBV therapy, serum HCV...
**Table 1 Baseline characteristics of patients in this study**

<table>
<thead>
<tr>
<th>Baseline characteristics</th>
<th>HCV mono-infection (N = 60)</th>
<th>HCV/human immunodeficiency virus co-infection (N = 36)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>50.5 ± 10.7</td>
<td>41.4 ± 8.5</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>Sex (male)</td>
<td>44 (73.3)</td>
<td>30 (63.3)</td>
<td>0.321</td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td>24.2 ± 3.6</td>
<td>22.3 ± 3.5</td>
<td>0.013*</td>
</tr>
<tr>
<td>Aspartate aminotransferase (IU/L)</td>
<td>52.3 ± 37.8</td>
<td>44.0 ± 21.5</td>
<td>0.229</td>
</tr>
<tr>
<td>Alanine aminotransferase (IU/L)</td>
<td>62.5 ± 52.1</td>
<td>61.9 ± 61.2</td>
<td>0.959</td>
</tr>
<tr>
<td>Platelet count (10⁹/L)</td>
<td>199.3 ± 76.0</td>
<td>209.0 ± 68.0</td>
<td>0.530</td>
</tr>
<tr>
<td>Log₁₀ HCV RNA (IU/ml)</td>
<td>6.2 ± 0.7</td>
<td>6.2 ± 0.9</td>
<td>0.844</td>
</tr>
<tr>
<td>HCV genotype</td>
<td></td>
<td></td>
<td>0.005*</td>
</tr>
<tr>
<td>GT1a</td>
<td>32 (53.3)</td>
<td>31 (86.1)</td>
<td></td>
</tr>
<tr>
<td>GT1b</td>
<td>24 (40.0)</td>
<td>4 (11.1)</td>
<td></td>
</tr>
<tr>
<td>GT1: not subtyped</td>
<td>4 (6.7)</td>
<td>1 (2.8)</td>
<td></td>
</tr>
<tr>
<td>APRI score</td>
<td>1.0 ± 1.5</td>
<td>0.6 ± 0.3</td>
<td>0.032*</td>
</tr>
<tr>
<td>Mac-2 binding protein glycosylation isomer (cutoff index)</td>
<td>2.2 ± 2.0</td>
<td>1.9 ± 2.2</td>
<td>0.508</td>
</tr>
<tr>
<td>Transient elastography (kPa)</td>
<td>12.1 ± 10.5</td>
<td>11.3 ± 12.8</td>
<td>0.725</td>
</tr>
<tr>
<td>Magnetic resonance elastography (kPa)</td>
<td>3.4 ± 1.1</td>
<td>3.0 ± 1.1</td>
<td>0.080</td>
</tr>
<tr>
<td>Previous peglated interferon/ribavirin therapy</td>
<td>13 (21.7)</td>
<td>6 (16.7)</td>
<td>0.607</td>
</tr>
</tbody>
</table>

Note: Data expressed as mean ± SD or n (%).

Abbreviations: APRI, alanine aminotransferase/platelet ratio index; GT1, genotype 1; HCV, hepatitis C virus.

* p < 0.05.

Regarding treatment outcome, SVR12 rate of the cohort was 97.9% (94 of 96). Of them, three patients experienced virological relapse at week 24 of follow-up and thus overall SVR24 was 94.8% (91 of 96). The HCV mono-infected and co-infected groups achieved comparable SVR12 (98.3% [59 of 60] vs. 97.2% [35 of 36], p = 1.000) and SVR24 (93.3% [56 of 60] vs. 97.2% [35 of 36], p = 0.647). Moreover, treatment-naïve and treatment-experience patients achieved similar SVR12 (97.4% [75 of 77] vs. 100% [19 of 19], p = 1.000) and SVR24 (93.5% [72 of 77] vs. 100% [19 of 19], p = 0.579).

**Relationship between baseline Mac-2-binding protein glycosylation isomer levels and other clinical parameters**

The relationship between serum M2BPGi levels and clinical parameters at baseline was examined. A positive correlation was found between M2BPGi and age (r = 0.460, p < 0.001), AST (r = 0.543, p < 0.001) and ALT (r = 0.293, p = 0.004). A negative correlation was found between M2BPGi and platelet counts (r = -0.368, p < 0.001). There was no correlation between M2BPGi and other clinical parameters (sex, BMI and HCV RNA level).

Among fibrosis markers at baseline, M2BPGi level was strongly correlated with MRE (r = 0.702, p < 0.001) with a moderate correlation with TE (r = 0.668, p < 0.001) and APRI (r = 0.527, p < 0.001). APRI were moderately correlated with MRE (r = 0.476, p < 0.001) and TE (r = 0.475, p < 0.001). Moreover, there was a strong correlation between TE and MRE (r = 0.759, p < 0.001).

**Diagnostic performance of fibrosis markers at baseline**

Using MRE as the reference methodology, the diagnostic performance of TE, M2BPGi and APRI at baseline were calculated by the area under the ROC curves (AUROCs; Figure 2). Based on MRE, AUROCs for TE in distinguishing significant fibrosis (≥F2), advanced fibrosis (≥F3) and cirrhosis (F4) were 0.88 (0.81–0.95, p < 0.001), 0.94 (0.89–0.99, p < 0.001) and 0.95 (0.90–1.00, p < 0.001), respectively. The corresponding figures for M2BPGi were 0.86 (0.79–0.94, p < 0.001), 0.93 (0.87–0.98, p < 0.001) and 0.96 (0.92–1.00, p < 0.001), respectively. For APRI, the corresponding values were 0.73 (0.64–0.83, p < 0.001), 0.80 (0.70–0.90, p < 0.001) and 0.88 (0.78–0.97, p < 0.001), respectively.
Changes and correlations of fibrosis markers at sustained virological response 24 weeks after treatment

Overall, all fibrosis markers were significantly changed from baseline to the time of SVR24. Specifically, liver stiffness evaluated by MRE decreased significantly from baseline to SVR24 (3.2 ± 1.1 vs. 2.8 ± 0.8 kPa, p < 0.001). The corresponding figures for liver stiffness measurement using TE were 11.8 ± 11.3 versus 8.5 ± 7.4 kPa (p < 0.001). Regarding serum fibrosis markers, the mean levels of M2BPGi at baseline and SVR24 were 2.1 ± 2.1 and 0.9 ± 0.9 COI, respectively (p < 0.001), while the corresponding values for APRI were 0.8 ± 1.2 and 0.3 ± 0.3, respectively (p < 0.001).

The correlations between various fibrosis markers at SVR24 were also determined. M2BPGi level at this time point was moderately correlated with MRE (r = 0.457, p < 0.001), TE (r = 0.549, p < 0.001) and APRI (r = 0.438, p < 0.001). The APRI was weakly correlated with MRE (r = 0.294, p = 0.004) and had moderate
correlation with TE \( r = 0.441, p < 0.001 \). In addition, there was a moderate correlation between TE and MRE \( r = 0.587, p < 0.001 \); Figure 1d–f).

Figure 3 demonstrates the changes of fibrosis markers from baseline to SVR24 in relation to treatment response. Liver stiffness values measured by MRE decreased significantly from baseline to SVR24 in responders (3.3 ± 1.1 vs. 2.8 ± 0.8 kPa, \( p < 0.001 \)) but the significance was not in non-responders (2.7 ± 0.6 vs. 2.5 ± 0.6 kPa, \( p = 0.433 \)) (Figure 3a). For TE measurement, the corresponding figures in responders were 12.1 ± 11.6 versus 8.7 ± 7.5 kPa \( p < 0.001 \), while in non-responders were 7.1 ± 2.4 versus 5.6 ± 2.4 kPa \( p = 0.021 \); Figure 3b). Regarding M2BPGi, the levels at baseline and SVR24 in responders were 2.2 ± 2.1 versus 0.9 ± 0.9 COI \( p < 0.001 \), while in non-responders were 1.3 ± 1.2 versus 1.2 ± 1.0 \( p = 0.480 \); Figure 3c). Among responders, there were three patients whose M2BPGi levels increased significantly at SVR24 compared with their baseline levels. Clinical characteristics of these patients are shown in Table S1. For APRI, the levels at baseline and SVR24 in responders were 0.8 ± 1.3 versus 0.3 ± 0.3 \( p < 0.001 \), while in non-responders were 0.8 ± 0.6 versus 0.3 ± 0.2 \( p = 0.134 \); Figure 3d).

**Dynamic changes of Mac-2-binding protein glycosylation isomer according to treatment response**

Details of serum M2BPGi decline during and after HCV therapy in relation to treatment response are shown in Figure 4. As mentioned, serum M2BPGi levels gradually declined during and after therapy in patients achieving SVR24 but not in patients without SVR. In the responders, mean M2BPGi at baseline, weeks 4, EOT, SVR12 and SVR24 were as follows: 2.2 ± 2.1, 1.4 ± 1.5, 1.2 ± 1.3, 0.9 ± 1.0 and 0.9 ± 0.9 COI, respectively (all \( p < 0.001 \) compared with baseline). The corresponding figures for non-responders were 1.3 ± 1.2, 1.0 ± 0.8, 0.9 ± 0.9, 1.0 ± 0.9 and 1.2 ± 1.0 COI, respectively (all \( p > 0.05 \) compared with baseline).

**FIGURE 3** Changes of fibrosis markers from baseline to sustained virological response at 24 weeks after treatment (SVR24) according to treatment response: (a) magnetic resonance elastography (MRE), (b) transient elastography (TE), (c) Mac-2 binding protein glycosylation isomer (M2BPGi), (d) aspartate aminotransferase/platelet ratio index (APRI). COI, cutoff index.
Factors associated with decline of Mac-2-binding protein glycosylation isomer levels after hepatitis C virus therapy

Univariate and multivariate analyses were calculated to identify baseline factors that were associated with decline serum M2BPGi levels (≥50% from baseline). These factors included age, sex, BMI, HIV status, previous PEG-IFN/RBV treatment, AST, ALT, platelet counts, HCV sub-genotype, HCV RNA level and liver stiffness staging assessed by MRE. In univariate analysis, parameters associated with reduced M2BPGi were old age, high baseline AST and ALT levels, HCV mono-infection and advanced fibrosis (≥F3). In multivariate analysis, high baseline ALT level, HCV mono-infection and advanced fibrosis were independent factors associated with M2BPGi reduction (Table 2).

DISCUSSION

A NEW PARADIGM of HCV therapy has improved substantially after the development of DAAs that are specifically addressed to viral targets in the HCV life cycle. The combination of EBR (NS5A inhibitor) and GZR (NS3/4A protease inhibitor) is a once-daily, fixed-dose tablet that has been approved for treating chronic HCV GT1 or GT4 infection. This combination with or without weight-adjusted RBV for 12–16 weeks displays high rates of SVR in GT1–infected individuals, including treatment-naïve or treatment-experienced patients. For instance, a phase 3 randomized controlled open label trial showed that SVR was achieved by 92.4% of patients treated with EBR/GZR for 12 weeks and 98.1% of patients given EBR/GZR plus

<table>
<thead>
<tr>
<th>Factors</th>
<th>Category</th>
<th>Univariate analysis OR (95% CI)</th>
<th>p</th>
<th>Multivariate analysis OR (95% CI)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>≥50 vs. &lt;50</td>
<td>3.76 (1.57–9.03)</td>
<td>0.003*</td>
<td>2.11 (0.72–6.21)</td>
<td>0.174</td>
</tr>
<tr>
<td>Sex</td>
<td>Male vs. female</td>
<td>2.26 (0.83–6.19)</td>
<td>0.112</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body mass index</td>
<td>≥24 vs. &lt;24</td>
<td>1.68 (0.73–3.80)</td>
<td>0.226</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human immunodeficiency positivity</td>
<td>No vs. yes</td>
<td>5.16 (2.26–13.94)</td>
<td>&lt;0.001*</td>
<td>4.88 (1.63–14.61)</td>
<td>0.005*</td>
</tr>
<tr>
<td>Previous HCV therapy</td>
<td>Yes vs. no</td>
<td>0.98 (0.36–2.67)</td>
<td>0.962</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aspartate aminotransferase (IU/L)</td>
<td>≥50 vs. &lt;50</td>
<td>3.56 (1.43–8.87)</td>
<td>0.007*</td>
<td>0.73 (0.15–3.56)</td>
<td>0.679</td>
</tr>
<tr>
<td>Alanine aminotransferase (IU/L)</td>
<td>≥60 vs. &lt;60</td>
<td>4.81 (1.88–12.33)</td>
<td>0.001*</td>
<td>7.42 (1.42–38.89)</td>
<td>0.018*</td>
</tr>
<tr>
<td>Platelet count (10^9/L)</td>
<td>≥200 vs. &lt;200</td>
<td>0.94 (0.42–2.10)</td>
<td>0.878</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HCV sub-genotype</td>
<td>GT1b vs. GT1a</td>
<td>1.32 (0.56–3.07)</td>
<td>0.528</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Log10 HCV RNA (IU/ml)</td>
<td>≥60 vs. &lt;60</td>
<td>1.32 (0.55–3.16)</td>
<td>0.532</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver fibrosis staging</td>
<td>F34 vs. F012</td>
<td>1.87 (1.31–2.69)</td>
<td>0.001*</td>
<td>1.75 (1.10–2.79)</td>
<td>0.019*</td>
</tr>
</tbody>
</table>

Abbreviations: CI, confident interval; HCV, hepatitis C virus; OR, odds ratio.
*p < 0.05.
RVB for 16 weeks. The corresponding figures in our cohort were 93.5% and 100%, respectively. Regarding HIV positivity, our results also showed that EBR/GZR therapy achieved comparable cure rates among patients with HCV mono-infection and HCV/HIV co-infection (93.3% and 97.2%, respectively). The SVR rate among HCV/HIV co-infected individuals in this cohort was in line with recent reports. Together, our results indicate that the EBR/GZR regimen is highly effective among Thai individuals infected with HCV G1, regardless of previous PEG-IFN/RBV treatment and HIV status.

It has been shown that significant fibrosis regression occurs after HCV eradication following DAA therapy, which is linked to a decreased risk of cirrhosis and HCC development. As mentioned, serial liver biopsies are associated with an increased risk of procedure-related complications. Thus, monitoring dynamic changes of fibrosis by reliable non-invasive methods is more practical than liver biopsy in clinical settings. In this study, MRE was selected as the reference imaging modality for fibrosis staging due to its high diagnostic accuracy. Based on recent meta-analysis, MRE displays AUROCs of 0.88, 0.93 and 0.92 for the prediction of ≥F2, ≥F3 and F4 fibrosis stages, respectively. Interestingly, a report of fiber quantitative analyses in patients with chronic HCV infection showed that MRE assessment significantly correlated with quantitative hepatic collagen and elastic fibers. Compared with TE, MRE exhibited a greater diagnostic performance for the detection of fibrosis and cirrhosis in prospective cohorts of patients with chronic viral hepatitis. Moreover, MRE provides the advantage over TE by visualizing the entire liver rather than sampling only small hepatic regions. Thus, MRE is considered an alternative method for liver biopsy in monitoring fibrotic changes after HCV therapy. In this report, we found that liver stiffness measured by MRE significantly decreased from baseline to the time of SVR24 in patients achieving SVR, but there was no significant change among non-responders. Of note, liver stiffness at baseline and SVR24 in responders were 3.3 and 2.8 kPa, which were similar to the data of a recent report (3.1 and 2.8 kPa, respectively). Together, these results indicate that DAA therapies result in a significant improvement in liver stiffness assessed by MRE in patients after achieving SVR.

Previous studies have demonstrated that serum M2BPGi is a reliable non-invasive fibrosis marker that might predict the efficacy of IFN-based and IFN-free DAA therapy. However, the dynamic changes of M2BPGi following antiviral therapy have not been well described. To our knowledge, this study is the first with emphasis on serial and dynamic changes of M2BPGi levels during and after DAA therapy. At baseline, our data showed that serum M2BPGi displayed diagnostic accuracy superior to that of APRI, which was in line with previous data. In fact, the AUROCs for assessing several stages of liver fibrosis using serum M2BPGi were almost comparable with those of TE. Beyond cross-sectional observations, M2BPGi could also be used to monitor potential fibrosis regression and predict treatment response in patients receiving DAA therapy. As shown in this study, patients achieving SVR displayed a significant and rapid reduction in serum M2BPGi at week 4 and throughout the follow-up periods as compared with pretreatment values. Moreover, serum M2BPGi at SVR24 had a better correlation with MRE compared with APRI.

Of note, the extent of M2BPGi decline at SVR24 was greater than that found in MRE measurement. These findings might reflect the improvement in necroinflammatory activities and fibrosis regression after DAA therapy. In this regard, the continuous and rapid decline in M2BPGi values within weeks during therapy could be linked to the reduction of necroinflammatory activities, as this marker was positively correlated with AST and ALT levels. This observation was in line with previous data demonstrating that serum M2BPGi quantification was partly correlated with serum aminotransferase levels. Nonetheless, further M2BPGi decline was also observed beyond EOT and throughout the follow-up, which might represent the contribution of ongoing fibrosis regression in patients who achieved SVR.

Several recent studies have demonstrated that HCC occurrence is the most common liver-related complication in patients with advanced fibrosis/cirrhosis who have achieved SVR with DAA therapy. To this end, monitoring simple non-invasive markers after treatment can help to identify individuals at high risk of HCC. Besides its role as a reliable marker of liver fibrosis, serum M2BPGi has another clinical utility as a predictor of future HCC development in patients with chronic HCV infection. For example, a recent report demonstrated that M2BPGi values >1.75 COI after achieving SVR were independently predictive for early HCC occurrence in patients with chronic HCV infection treated with DAAs. In this respect, it seems that M2BPGi at the time of SVR is able to predict the clinical outcome of patients with pre-existing advanced fibrosis/cirrhosis. Although the specific role of M2BPGi that links to HCC progression has not been entirely explored, previous in vitro observations suggested that activated stellate cell-derived M2BP might be a key modulator in both fibrogenesis and hepatocarcinogenesis. Together, our data and previous reports indicate that serum M2BPGi can be used as a surrogate marker for monitoring the dynamic changes of liver fibrosis during DAA therapy as well as an accurate tool for predicting HCC development after SVR. Its clinical utility may be particularly suitable in resource-limited settings where imaging-based modalities such as MRE and TE are not widely accessible.

This study had some limitations as it included a small number of patients, particularly co-infected individuals, and a relative short period after completion of the therapy. Further large-scale and longer follow-up studies are warranted to confirm these observations. In addition, compared with the co-infected group, patients with HCV mono-infection had a significantly higher APRI score, although there were no significant differences between groups in terms of serum M2BPGi and elastography evaluated by TE and MRE. However, in a recent propensity score-matched cohort, M2BPGi levels were significantly higher in patients with HIV/HCV co-infection compared with levels in the HCV mono-infected group. Such a discrepancy probably contributed to the difference in study design, as our report enrolled unmatched patients with or without HIV infection.
In conclusion, our data showed that HCV eradication with EBR/ GZR therapy was associated with significant fibrosis improvement, as measured using MRE, TE and serum fibrosis markers. Compared with APRI, serum M2BP/Gi represented a better non-invasive marker for the assessment of liver fibrosis at baseline and after DAA therapy. In patients achieving SVR24, serum M2BP/Gi gradually declined during and after the administration of DAA, particularly in individuals with significant fibrosis at baseline.

ACKNOWLEDGEMENTS

WE WOULD LIKE to thank Center of Excellence in Hepatitis and Liver Cancer, Faculty of Medicine, Chulalongkorn University and thank to Ms. Pantajaree Hiranrat (Sonographer School, Faculty of Health Science Technology, Chulabhorn Royal Academy, Bangkok, Thailand) for technical support of MRE measurement.

CONFLICT OF INTEREST

This study was funded by Sysmex Asia Pacific and Merck, the Thailand Research Fund (TRF) Senior Research Scholar (RTA6280004) and Ratchadaphiseksomphot Endowment Fund (CU_GR_63_120_30_27), Chulalongkorn University. Pisit Tangkijvanich has received research grants from Sysmex Asia Pacific and Merck. Natthaya Chuaypen, Salyavit Chittmittrap, Anchalee Avihingsanon, Surachate Siripongsakun, Jongkonnee Wongpiyabovorn, Nattaporn Tanpowpong and Yasuhiito Tanaka have no conflict of interest.

ORCID

Natthaya Chuaypen https://orcid.org/0000-0002-5415-510X
Anchalee Avihingsanon https://orcid.org/0000-0003-3222-9611
Surachate Siripongsakun https://orcid.org/0000-0001-9848-6202
Jongkonnee Wongpiyabovorn https://orcid.org/0000-0002-3549-6718
Yasuhiito Tanaka https://orcid.org/0000-0002-2473-6966
Pisit Tangkijvanich https://orcid.org/0000-0002-2926-8671

REFERENCES

7. Ioannou GN, Feld JJ. What are the benefits of a sustained virologic response to direct-acting antiviral therapy for hepatitis C virus infection?. Gastroenterology. 2019;156:446–60e2.


SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section at the end of this article.